MCID: HLL005
MIFTS: 25

Hallucinogen Dependence

Categories: Mental diseases

Aliases & Classifications for Hallucinogen Dependence

Summaries for Hallucinogen Dependence

Disease Ontology : 12 A drug dependence that involves the continued use of hallucinogenic drugs despite problems related to use of the substance.

MalaCards based summary : Hallucinogen Dependence is related to autoimmune inner ear disease and psychotic disorder. An important gene associated with Hallucinogen Dependence is CNR1 (Cannabinoid Receptor 1), and among its related pathways/superpathways are GABAergic synapse and Ca, cAMP and Lipid Signaling. The drugs Clonidine and Dronabinol have been mentioned in the context of this disorder. Related phenotype is behavior/neurological.

Related Diseases for Hallucinogen Dependence

Diseases related to Hallucinogen Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 autoimmune inner ear disease 10.1 CNR1 FAAH
2 psychotic disorder 10.0
3 hereditary multiple exostoses 9.9 CNR1 FAAH
4 alcoholic liver cirrhosis 9.7 CNR1 FAAH
5 rosai-dorfman disease 9.6 HCRTR1 HCRTR2
6 giant cell reparative granuloma 9.5 CNR1 FAAH PENK
7 colonic disease 9.5 HCRTR1 HCRTR2
8 orbit lymphoma 7.3 CNR1 CSMD1 DAGLB FAAH HCRTR1 HCRTR2

Graphical network of the top 20 diseases related to Hallucinogen Dependence:



Diseases related to Hallucinogen Dependence

Symptoms & Phenotypes for Hallucinogen Dependence

MGI Mouse Phenotypes related to Hallucinogen Dependence:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.1 CNR1 CSMD1 FAAH HCRTR1 HCRTR2 PENK

Drugs & Therapeutics for Hallucinogen Dependence

Drugs for Hallucinogen Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 2, Phase 3 4205-90-7 2803
2
Dronabinol Approved, Illicit Phase 2, Phase 3, Phase 1 1972-08-3 16078 2978
3
Lofexidine Approved, Investigational Phase 2, Phase 3 31036-80-3 30668
4
Naltrexone Approved, Investigational, Vet_approved Phase 2, Phase 3 16590-41-3 5360515
5
Nabilone Approved, Investigational Phase 2, Phase 3 51022-71-0 5284592
6 Hallucinogens Phase 2, Phase 3, Phase 1
7 Psychotropic Drugs Phase 2, Phase 3, Phase 1
8 Central Nervous System Depressants Phase 2, Phase 3
9 Adrenergic Agents Phase 2, Phase 3
10 Adrenergic Agonists Phase 2, Phase 3
11 Adrenergic alpha-2 Receptor Agonists Phase 2, Phase 3
12 Adrenergic alpha-Agonists Phase 2, Phase 3
13 Analgesics Phase 2, Phase 3, Phase 1
14 Analgesics, Non-Narcotic Phase 2, Phase 3, Phase 1
15 Antihypertensive Agents Phase 2, Phase 3
16 Autonomic Agents Phase 2, Phase 3
17 Cannabinoid Receptor Agonists Phase 2, Phase 3, Phase 1
18 Hormone Antagonists Phase 2, Phase 3, Phase 1
19 Hormones Phase 2, Phase 3, Phase 1
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3, Phase 1
21 Narcotic Antagonists Phase 2, Phase 3
22 Narcotics Phase 2, Phase 3
23 Neurotransmitter Agents Phase 2, Phase 3, Phase 1
24 Peripheral Nervous System Agents Phase 2, Phase 3, Phase 1
25 Sympatholytics Phase 2, Phase 3
26 Analgesics, Opioid Phase 2, Phase 3
27 Antiemetics Phase 2, Phase 3
28 Gastrointestinal Agents Phase 2, Phase 3
29 Anti-Anxiety Agents Phase 2, Phase 3
30 Tranquilizing Agents Phase 2, Phase 3
31
Ethanol Approved Phase 2 64-17-5 702
32 Peppermint oil Approved Phase 2
33
Diphenhydramine Approved Phase 2 58-73-1, 147-24-0 3100
34
Histamine Approved, Investigational Phase 2 75614-87-8, 51-45-6 774
35
Promethazine Approved Phase 2 60-87-7 4927
36
Cocaine Approved, Illicit Phase 2 50-36-2 5760 446220
37
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
38
Peppermint Approved, Nutraceutical Phase 2
39
Psilocybine Investigational Phase 2 520-52-5
40 Anti-Infective Agents Phase 2
41 Anti-Infective Agents, Local Phase 2
42 Parasympatholytics Phase 2
43 Anesthetics Phase 2
44 Anesthetics, Local Phase 2
45 Anti-Allergic Agents Phase 2
46 Antipruritics Phase 2
47 Dermatologic Agents Phase 2
48 Histamine Antagonists Phase 2
49 Histamine H1 Antagonists Phase 2
50
Histamine Phosphate Phase 2 51-74-1 65513

Interventional clinical trials:

(show all 16)

id Name Status NCT ID Phase Drugs
1 Combined Pharmacotherapy for Cannabis Dependency Completed NCT01020019 Phase 2, Phase 3 Dronabinol;Placebo;Lofexidine
2 Dronabinol Naltrexone Treatment for Opioid Dependence Completed NCT01024335 Phase 2, Phase 3 injectable naltrexone and dronabinol;Naltrexone and placebo
3 Nabilone for Cannabis Dependence: A Pilot Study Recruiting NCT01347762 Phase 2, Phase 3 Nabilone;Placebo
4 Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia Recruiting NCT01598896 Phase 2, Phase 3 Dronabinol;Clonidine;Placebo
5 Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence Unknown status NCT01534494 Phase 2 Psilocybin
6 Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence Completed NCT01747850 Phase 2 Sativex;Placebo spray
7 Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal Completed NCT00480441 Phase 2 Dronabinol;Placebo
8 Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse Completed NCT00373503 Phase 2 Lofexidine;dronabinol;Marijuana
9 Dronabinol Treatment for Marijuana Addiction Completed NCT00217971 Phase 2 Dronabinol;Placebo
10 A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence Recruiting NCT02061293 Phase 2 Psilocybin;Diphenhydramine
11 Psilocybin-facilitated Treatment for Cocaine Use Recruiting NCT02037126 Phase 2 Psilocybin;Diphenhydramine
12 Ph1 Marinol Interaction Study - Part 2 - 1 Completed NCT00490269 Phase 1 Placebo;Dronabinol
13 Ph1 Marinol Interaction Study - Part 1 - 1 Terminated NCT00438139 Phase 1 Dronabinol
14 Fixed or Self-Titrated Dosages of Sativex on Cannabis Users Completed NCT01748799 Sativex;Placebo
15 Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study Recruiting NCT01943994 Psilocybin-assisted treatment;Nicotine Replacement Therapy (NRT)
16 E-cigarette THC Study Not yet recruiting NCT02955329 Tetrahydrocannabinol

Search NIH Clinical Center for Hallucinogen Dependence

Genetic Tests for Hallucinogen Dependence

Anatomical Context for Hallucinogen Dependence

Publications for Hallucinogen Dependence

Articles related to Hallucinogen Dependence:

id Title Authors Year
1
Evidence for a hallucinogen dependence syndrome developing soon after onset of hallucinogen use during adolescence. ( 17019896 )
2006

Variations for Hallucinogen Dependence

Expression for Hallucinogen Dependence

Search GEO for disease gene expression data for Hallucinogen Dependence.

Pathways for Hallucinogen Dependence

Pathways related to Hallucinogen Dependence according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.85 CNR1 DAGLB FAAH
2 11.35 CNR1 DAGLB
3 10.47 CNR1 DAGLB
4 10.07 CNR1 FAAH

GO Terms for Hallucinogen Dependence

Biological processes related to Hallucinogen Dependence according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.52 CNR1 PENK
2 glucose homeostasis GO:0042593 9.51 CNR1 CSMD1
3 chemical synaptic transmission GO:0007268 9.5 HCRTR1 HCRTR2 PENK
4 sensory perception of pain GO:0019233 9.49 CNR1 PENK
5 cellular response to hormone stimulus GO:0032870 9.48 HCRTR1 HCRTR2
6 feeding behavior GO:0007631 9.46 HCRTR1 HCRTR2
7 response to nicotine GO:0035094 9.43 CNR1 PENK
8 regulation of cytosolic calcium ion concentration GO:0051480 9.4 HCRTR1 HCRTR2
9 response to morphine GO:0043278 9.37 CNR1 PENK
10 arachidonic acid metabolic process GO:0019369 9.26 DAGLB FAAH
11 response to peptide GO:1901652 9.16 HCRTR1 HCRTR2
12 neuropeptide signaling pathway GO:0007218 9.13 HCRTR1 HCRTR2 PENK
13 regulation of circadian sleep/wake cycle, sleep GO:0045187 8.62 HCRTR1 HCRTR2

Molecular functions related to Hallucinogen Dependence according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 peptide binding GO:0042277 9.26 HCRTR1 HCRTR2
2 peptide hormone binding GO:0017046 9.16 HCRTR1 HCRTR2
3 acylglycerol lipase activity GO:0047372 8.96 DAGLB FAAH
4 orexin receptor activity GO:0016499 8.62 HCRTR1 HCRTR2

Sources for Hallucinogen Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....